Latent, a clinical AI company focused on accelerating patient access to life-saving medications, announced it has raised $80 million in a Series A funding round. The round was co-led by Spark Capital and Transformation Capital, with participation from Conviction, McKesson Ventures, General Catalyst, and Y Combinator.
The company is tackling a critical bottleneck in healthcare delivery: the gap between diagnosis and treatment. Despite advances in medicine, nearly half of critical cases in the United States face delays or denials in accessing prescribed therapies. These delays are often driven not by medical limitations but by administrative complexity, including clinical documentation requirements, payer rules, and pharmacy coordination.
Latent addresses this challenge through its Clinical Reasoning Engine, an AI-powered platform designed to perform complex clinical knowledge work. The system interprets patient data, evaluates drug eligibility criteria, extracts relevant clinical evidence, and coordinates workflows across providers, payers, and pharmacies. By integrating electronic health records, payer guidelines, and operational workflows into a unified system, the platform enables faster and more reliable transitions from diagnosis to treatment.
The company initially focused on prior authorization, one of the most complex and high-friction processes in healthcare. By automating clinical reasoning and documentation requirements, Latent has demonstrated the ability to reduce administrative burden while improving patient outcomes. It is now expanding its platform to support a broader range of clinical workflows where medical decision-making must be translated into action.
Latent reports that its platform currently helps more than 2 million patients annually access medications faster. Over the past year, the company has expanded rapidly, growing from four to more than 45 health system partners. It now works with 50 percent of the top 20 U.S. health systems, including major organizations such as Yale New Haven Health, Ochsner Health, Vanderbilt Health, Mount Sinai Health System, and UCLA Health. Across its deployments, the platform has reduced treatment denials by more than 30 percent and enabled clinicians to treat significantly more patients.
Looking ahead, Latent plans to extend its Clinical Reasoning Engine beyond reactive workflows. The company aims to proactively identify when patients should begin therapy and ensure adherence over time, addressing gaps where treatments are delayed, denied, or never initiated.
The new funding will be used to expand Latent’s footprint across health systems, deepen integrations across healthcare stakeholders, enhance platform reliability, and scale its team as it continues building infrastructure at the intersection of clinicians, patients, and payers.
